Abnormal PcG protein expression in Hodgkin's lymphoma. Relation with E2F6 and NFκB transcription factors

Journal of Pathology

Volumn 204, Issue 5, 2004, Pages 528-537

  Sánchez Beato, Margarita ^a   Sánchez, Esther ^b   García, Juan F ^a   Pérez Rosado, Alberto ^a   Montoya, María C ^a   Fraga, Mario ^a   Artiga, M Jesús ^a   Navarrete, Mercedes ^a   Abraira, Víctor ^c   Morente, Manuel ^a   Esteller, Manel ^a   Koseki, Haruhiko ^d   Vidal, Miguel ^e   Piris, Miguel A ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL NUESTRA SEÑORA DEL PRADO   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d RIKEN   (Japan)

^e CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

E2F6; Hodgkin; Lymphoma; NF B; Polycomb; Tissue microarray

Indexed keywords

CURCUMIN; HOMEODOMAIN PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PARAFFIN; POLYCOMB GROUP PROTEIN; PROTEIN BMI1; PROTEIN MEL18; PROTEIN PH1; PROTEIN RING1; PROTEIN RNF2; PROTEIN RYBP; REGULATOR PROTEIN; TRANSCRIPTION FACTOR E2F6; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CANCER SURVIVAL; CELL CYCLE; COMPLEX FORMATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; LYMPHOCYTE DIFFERENTIATION; LYMPHOID TISSUE; LYMPHOMA CELL; LYMPHOMA CELL LINE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN MICROARRAY; PROTEIN PROTEIN INTERACTION; STATISTICAL ANALYSIS; SURVIVAL TIME; TISSUE SECTION; TRANSCRIPTION REGULATION; TREATMENT FAILURE; TUMOR BIOPSY; UPREGULATION;

APOPTOSIS; B-LYMPHOCYTES; BLOTTING, WESTERN; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F6 TRANSCRIPTION FACTOR; ELECTROPHORESIS, CAPILLARY; FLUORESCENT ANTIBODY TECHNIQUE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOID TISSUE; NF-KAPPA B; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS; UBIQUITIN-PROTEIN LIGASES; ZINC FINGERS;

EID: 9744266772     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1661     Document Type: Article

References (51)

1. Jacobs JJ, van Lohuizen M. Polycomb repression: from cellular memory to cellular proliferation and cancer. Biochim Biophys Acta 2002; 1602: 151-161.
2. Simon JA, Tamkun JW. Programming off and on states in chromatin: mechanisms of Polycomb and trithorax group complexes. Curr Opin Genet Dev 2002; 12: 210-218.
3. Raaphorst FM, Otte AP, Meijer CJ. Polycomb-group genes as regulators of mammalian lymphopoiesis. Trends Immunol 2001; 22 682-690.
4. Lessard J, Sauvageau G. Polycomb group genes as epigenetic regulators of normal and leukemic hemopoiesis. Exp Hematol 2003; 31: 567-585.
5. Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF, Morrison SJ. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 2003; 425: 962-967.
6. Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003; 423: 302-305.
7. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003; 423 255-260.
8. Strutt H, Paro R. The Polycomb group protein complex of Drosophila melanogaster has different compositions at different target genes. Mol Cell Biol 1997; 17: 6773-6783.
9. Gunster MJ, Raaphorst FM, Hamer KM, et al. Differential expression of human Polycomb group proteins in various tissues and cell types. J Cell Biochem 2001; 81: 129-143.
10. Satijn DP, Otte AP. Polycomb group protein complexes: do different complexes regulate distinct target genes? Biochim Biophys Acta 1999; 1447: 1-16.
11. Schoorlemmer J, Marcos-Gutierrez C, Were F, et al. Ring1A is a transcriptional repressor that interacts with the Polycomb-M33 protein and is expressed at rhombomere boundaries in the mouse hindbrain. EMBO J 1997; 16: 5930-5942.
12. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298 1039-1043.
13. Satijn DP, Hamer KM, den Blaauwen J, Otte AP. The polycomb group protein EED interacts with YY1, and both proteins induce neural tissue in Xenopus embryos. Mol Cell Biol 2001; 21: 1360-1369.
14. Sewalt RG, van der Vlag J, Gunster MJ, et al. Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes. Mol Cell Biol 1998; 18: 3586-3595.
15. Satijn DP, Otte AP. RING1 interacts with multiple Polycomb-group proteins and displays tumorigenic activity. Mol Cell Biol 1999; 19: 57-68.
16. Hashimoto N, Brock HW, Nomura M, et al. RAE28, BMI1, and M33 are members of heterogeneous multimeric mammalian Polycomb group complexes. Biochem Biophys Res Commun 1998; 245: 356-365.
17. Alkema MJ, Bronk M, Verhoeven E, et al. Identification of Bmi1-interacting proteins as constituents of a multimeric mammalian polycomb complex. Genes Dev 1997; 11: 226-240.
18. Lessard J, Schumacher A, Thorsteinsdottir U, van Lohuizen M, Magnuson T, Sauvageau G. Functional antagonism of the Polycomb-Group genes eed and Bmi1 in hemopoietic cell proliferation. Genes Dev 1999; 13: 2691-2703.
19. Raaphorst FM, van Kemenade FJ, Fieret E, et al. Cutting edge: polycomb gene expression patterns reflect distinct B cell differentiation stages in human germinal centers. J Immunol 2000; 164: 1-4.
20. Raaphorst FM, Otte AP, van Kemenade FJ, et al. Distinct BMI-1 and EZH2 expression patterns in thymocytes and mature T cells suggest a role for Polycomb genes in human T cell differentiation. J Immunol 2001; 166: 5925-5934.
21. van der Lugt NM, Domen J, Linders K, et al. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 protooncogene. Genes Dev 1994; 8: 757-769.
22. Akasaka T, Tsuji K, Kawahira H, et al. The role of mel-18, a mammalian Polycomb group gene, during IL-7-dependent proliferation of lymphocyte precursors. Immunity 1997; 7: 135-146.
23. van Kemenade FJ, Raaphorst FM, Blokzijl T, et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 2001; 97: 3896-3901.
24. Alkema MJ, Jacobs H, van Lohuizen M, Berns A. Perturbation of B and T cell development and predisposition to lymphomagenesis in Emu Bmi1 transgenic mice require the Bmi1 RING finger. Oncogene 1997; 15: 899-910.
25. Haupt Y, Bath ML, Harris AW, Adams JM. bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. Oncogene 1993; 8: 3161-3164.
26. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 1991; 65: 737-752.
27. Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell 1991; 65: 753-763.
28. Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 1999; 13: 2678-2690.
29. Garcia E, Marcos-Gutierrez C, Lorente MdM, Moreno JC, Vidal M. RYBP, a new repressor protein that interacts with components of the mammalian Polycomb complex, and with the transcription factor YY1. EMBO J 1999; 18: 3404-3418.
30. Visser HP, Gunster MJ, Kluin-Nelemans HC, et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 2001; 112: 950-958.
31. Raaphorst FM, van Kemenade FJ, Blokzijl T, et al. Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol 2000; 157: 709-715.
32. Dukers DF, van Galen JC, Giroth C, et al. Unique Polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol 2004; 164: 873-881.
33. Raaphorst FM, Vermeer M, Fieret E, et al. Site-specific expression of Polycomb-group genes encoding the HPC-HPH/PRC1 complex in clinically defined primary nodal and cutaneous large B-cell lymphomas. Am J Pathol 2004; 164: 533-542.
34. Garcia JF, Camacho FI, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003; 101: 681-689.
35. Montalbán CJG, Abraira V, González-Camacho L, et al. Influence of biological markers on the outcome of Hodgkin's lymphoma. J Clin Oncol 2004; in press.
36. Fraga MF, Ballestar E, Montoya G, Taysavang P, Wade PA, Esteller M. The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucl Acids Res 2003; 31: 1765-1774.
37. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999; 397: 164-168.
38. Trimarchi JM, Fairchild B, Wen J, Lees JA. The E2F6 transcription factor is a component of the mammalian Bmi1-containing polycomb complex. Proc Natl Acad Sci USA 2001; 98: 1519-1524.
39. Philip S, Kundu GC. Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through Ikappa Balpha/IKK signaling pathways, and curcumin (diferuloylmethane) down-regulates these pathways. J Biol Chem 2003; 278: 14 487-14 497.
40. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and Ikappa Balpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003; 101: 1053-1062.
41. Foulds G, Etzkorn F. A capillary electrophoresis mobility shift assay for protein-DNA binding affinities free in solution. Nucl Acids Res 1998; 26: 4304-4305.
42. Hinz M, Lemke P, Anagnostopoulos I, et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 2002; 196: 605-617.
43. Schlisio S, Halperin T, Vidal M, Nevins JR. Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J 2002; 21: 5775-5786.
44. Ogawa H, Ishiguro K, Gaubatz S, Livingston DM, Nakatani Y. A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 cells. Science 2002; 296: 1132-1136.
45. Gaubatz S, Wood JG, Livingston DM. Unusual proliferation arrest and transcriptional control properties of a newly discovered E2F family member, E2F-6. Proc Natl Acad Sci USA 1998; 95: 9190-9195.
46. Cartwright P, Muller H, Wagener C, Holm K, Helin K. E2F-6: a novel member of the E2F family is an inhibitor of E2F-dependent transcription. Oncogene 1998; 17: 611-623.
47. Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996; 87: 4340-4347.
48. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100: 2961-2969.
49. Asano H, Ishida A, Hasegawa M, et al. The mouse Mel-18 'RING-finger' gene: genomic organization, promoter analysis and chromosomal assignment. DNA Seq 1993; 3: 369-377.
50. Atsuta T, Fujimura S, Moriya H, Vidal M, Akasaka T, Koseki H. Production of monoclonal antibodies against mammalian Ring1B proteins. Hybridoma 2001; 20: 43-46.
51. Suzuki M, Mizutani-Koseki Y, Fujimura Y, et al. Involvement of the Polycomb-group gene Ring1B in the specification of the anterior-posterior axis in mice. Development 2002; 129: 4171-4183.